PURPOSE: To establish the potential for tumour heterogeneity in non-small cell lung cancer (NSCLC) as assessed by CT texture analysis (CTTA) to provide an independent marker of survival for patients with NSCLC. MATERIALS AND METHODS: Tumour heterogeneity was assessed by CTTA of unenhanced images of primary pulmonary lesions from 54 patients undergoing (18)F-fluorodeoxyglucose (FDG) PET-CT for staging of NSCLC. CTTA comprised image filtration to extract fine, medium and coarse features with quantification of the distribution of pixel values (uniformity) within the filtered images. Receiver operating characteristics identified thresholds for PET and CTTA parameters that were related to patient survival using Kaplan-Meier analysis. RESULTS: The median (range) survival was 29.5 (1-38) months. 24, 10, 14 and 6 patients had tumour stages I, II, III and IV respectively. PET stage and tumour heterogeneity assessed by CTTA were significant independent predictors of survival (PET stage: Odds ratio 3.85, 95% confidence limits 0.9-8.09, P = 0.002; CTTA: Odds ratio 56.4, 95% confidence limits 4.79-666, p = 0.001). SUV was not a significantly associated with survival. CONCLUSION: Assessment of tumour heterogeneity by CTTA of non-contrast enhanced images has the potential for to provide a novel, independent predictor of survival for patients with NSCLC. KEY POINTS: Computed tomography is a routine staging procedure in non-small cell lung cancer. CT texture analysis (CTTA) can quantify heterogeneity within these lung tumours. CTTA seems to offer a novel independent predictor of survival for NSCLC. CTTA could contribute to disease risk-stratification for patients with NSCLC.
PURPOSE: To establish the potential for tumour heterogeneity in non-small cell lung cancer (NSCLC) as assessed by CT texture analysis (CTTA) to provide an independent marker of survival for patients with NSCLC. MATERIALS AND METHODS:Tumour heterogeneity was assessed by CTTA of unenhanced images of primary pulmonary lesions from 54 patients undergoing (18)F-fluorodeoxyglucose (FDG) PET-CT for staging of NSCLC. CTTA comprised image filtration to extract fine, medium and coarse features with quantification of the distribution of pixel values (uniformity) within the filtered images. Receiver operating characteristics identified thresholds for PET and CTTA parameters that were related to patient survival using Kaplan-Meier analysis. RESULTS: The median (range) survival was 29.5 (1-38) months. 24, 10, 14 and 6 patients had tumour stages I, II, III and IV respectively. PET stage and tumour heterogeneity assessed by CTTA were significant independent predictors of survival (PET stage: Odds ratio 3.85, 95% confidence limits 0.9-8.09, P = 0.002; CTTA: Odds ratio 56.4, 95% confidence limits 4.79-666, p = 0.001). SUV was not a significantly associated with survival. CONCLUSION: Assessment of tumour heterogeneity by CTTA of non-contrast enhanced images has the potential for to provide a novel, independent predictor of survival for patients with NSCLC. KEY POINTS: Computed tomography is a routine staging procedure in non-small cell lung cancer. CT texture analysis (CTTA) can quantify heterogeneity within these lung tumours. CTTA seems to offer a novel independent predictor of survival for NSCLC. CTTA could contribute to disease risk-stratification for patients with NSCLC.
Authors: H L van Westreenen; M Westerterp; P M M Bossuyt; J Pruim; G W Sloof; J J B van Lanschot; H Groen; J Th M Plukker Journal: J Clin Oncol Date: 2004-09-15 Impact factor: 44.544
Authors: Andrew Wirth; Marcus Foo; John F Seymour; Michael P Macmanus; Rodney J Hicks Journal: Int J Radiat Oncol Biol Phys Date: 2008-03-04 Impact factor: 7.038
Authors: Hubert Vermeersch; David Loose; Hamphrey Ham; Andreas Otte; Christophe Van de Wiele Journal: Eur J Nucl Med Mol Imaging Date: 2003-10-22 Impact factor: 9.236
Authors: Thomas Perrin; Abhishek Midya; Rikiya Yamashita; Jayasree Chakraborty; Tome Saidon; William R Jarnagin; Mithat Gonen; Amber L Simpson; Richard K G Do Journal: Abdom Radiol (NY) Date: 2018-12
Authors: Mu Zhou; Lawrence Hall; Dmitry Goldgof; Robin Russo; Yoganand Balagurunathan; Robert Gillies; Robert Gatenby Journal: Transl Oncol Date: 2014-02-01 Impact factor: 4.243